Key Capital Announces Terminal Liver Cancer Trial Results

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
290
Key Capital Announces Terminal Liver Cancer Trial Results Publication

SCOTTSDALE, AZ--(Marketwired - Apr 13, 2017) -  KEY CAPITAL CORPORATION ( OTC PINK : KCPC ) advises publication of the highly successful liver cancer trial results of its licensed Immunitor Inc. immunotherapy. As announced last month, the Immunitor Inc. licensed immunotherapy, and particularly its liver cancer immunotherapy product, will be implemented by Key Capital, conditional to all required approvals, initially by pursuing the unmet medical need in the Costa Rica and Guatemala territories.

Key Capital cites below the following press release, as issued by Immunitor Inc., reporting the success of the immunotherapy:

Groundbreaking immunotherapy trial in advanced liver cancer

Immunitor Inc., is pleased to report publication of a first ever successful trial in the oncoimmunology field showing that the once-daily tablet of oral immunotherapeutic vaccine, hepcortespenlisimut-L (Hepko-V5), was safe and highly effective in treating patients with advanced liver cancer -- inoperable hepatocellular carcinoma (HCC) . The open-label Phase II study conducted in 75 patients with late-stage HCC appeared in open access Journal of Hepatocellular Carcinoma ( https://www.dovepress.com/articles.php?article_id=32377 ).

The overall survival observed in the published study was outstanding -- over 90% of patients were alive after median 12 months of follow up -- by comparison only about 10% survive after one year of treatment with sorafenib . This study has also shown that after median 2 months of treatment 50 out 75 patients had their hepatic tumor marker, alpha-fetoprotein or AFP, declined, which indicates that two thirds (66.7%) of studied population responded to immunotherapy, since the decrease in AFP was correlated with tumor shrinkage. Those who had AFP down to normal levels experienced tumor clearance, implying that they were cured. There were 12 patients (16%) in the study who ended up with normalized AFP below 10 IU/ml. No adverse events or toxicity were observed at any time -- an observation in line with the experience in over 10,000 people who took V5 for the past 15 years in more than 30 countries for clinical indications such as liver cirrhosis and hepatitis. Considering that no validated immunotherapy for liver cancer has emerged after 20 years of research efforts, these results are highly promising. An ongoing Phase III study at the Mongolian National Cancer Center is aimed to confirm the potential of hepcortespenlisimut-L in placebo-controlled, randomized setting.

HCC is the second most common cause of death from cancer, estimated to be responsible for 788,000 deaths or 9.1% of total cancer fatalities in 2015. Aside from surgery, the only available option is the FDA-approved chemotherapy, sorafenib (NEXAVAR), which prolongs life by 2.8 months, results in 2% of partial clinical response, but no cure. According to the American Cancer Society 40,710 new cases of HCC and intrahepatic bile duct cancer will be diagnosed in 2017 in the United States. "While HCC rates have tripled since 1980, they are still relatively low in North America and most of Europe, but it is a major cause of death in developing countries," said Dr. Allen Bain -- director of Vancouver-based Immunitor Inc. "Half of liver cancer patients are in mainland China," added Mr. Alan Reid -- head of Hong Kong-registered Immunitor China Ltd -- a company set up to address the unmet need of Asian market. "Africa has the remaining share of burden," joined Mr. Paul Heslop -- the company manager in Johannesburg, South Africa. Mr. Valeryi Kalashnikov -- representative in Moscow, Russia -- noted: "Eastern Europe and Russian Federation are additional target countries with high prevalence of hepatitis, cirrhosis and liver cancer." Dr. Aldar Bourinbaiar, CEO of Mongolia-based Immunitor LLC, commented: "The results of this trial are good news to patients with HCC, who now have life-saving option . We are deeply satisfied by outcome of this study, which has all the signs of long-awaited breakthrough in liver cancer. This trial is yet another proof-of-concept for our oral vaccines platform designed to counteract cancer-associated inflammation through induction of immune tolerance, explaining why our vaccine can cure cancer, but without any evidence of toxicity." The co-founder of the company, Mr. Vichai Jirathitikal, concluded: "Hepko can control HCC the same way as V5 has shown for hepatitis and cirrhosis."

For further information: See www.keycapitalgroup.com and www.immunitor.com  

About Immunitor Immunitor Inc. is a privately held, commercial stage biopharmaceutical company with headquarters in Vancouver, Canada ( www.immunitor.com ) and offices in Beijing, Johannesburg, Moscow and Ulaanbaatar. Immunitor's strength resides in its proprietary oral vaccine platform validated by numerous clinical trials conducted over the past 15 years. Immunitor manufactures several immunotherapy products addressing major health problems, i.e., in infectious diseases area: HIV, hepatitis, influenza, malaria, drug-resistant fungal and microbial infections including tuberculosis such as MDR-TB; in autoimmune and metabolic diseases: i.e., renal failure, thyroiditis, Alzheimer disease, hypertension, atherosclerosis, obesity and diabetes; and recently in oncology space, with several candidates currently being investigated. The immediate goal of Immunitor is to address the unmet need in a wide range of liver-related diseases. A Phase II trial in patients with cholangiocarcinoma -- second most common form of liver cancer affecting bile ducts -- has been initiated last month. Soon, another immunotherapy will be deployed with intent to treat pancreatic cancer, which has the worst prognosis out of all forms of cancer. Based on encouraging preliminary data in HCC patients, hepcortespenlisimut-L has applied and received orphan drug designation from the U.S. Food and Drug Administration (FDA), which clears the path toward approval in US market.

Disclaimer: Statements made in this press release that express the Company or management's intentions, plans, beliefs, expectations, or predictions of future events, are forward-looking statements. The words "believe," "expect," "intend," "estimate," "anticipate," "will" and similar expressions are intended to further identify such forward-looking statements, although not all forward-looking statements contain these identifying words. Those statements are based on many assumptions and are subject to many known and unknown risks, uncertainties and other factors that could cause the Company's actual activities, results or performance to differ materially from those anticipated or projected in such forward-looking statements. The Company cannot guarantee future financial results, levels of activity, performance or achievements and investors should not place undue reliance on the Company's forward-looking statements.

Key Capital Corporation Christopher Nichols +1 (480) 745-2565 info@keycapitalgroup.com Immunitor Dr. Allen Bain +1 (360) 566-2194 info@immunitor.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

JOYY’s Ad Engine Gives Q3 Growth Some Real Teeth Now

Updated Category News Views 107

Three engines are finally pulling the cart at JOYY, and that is a far more interesting sight than another quarter of livestreaming merely holding together. The company reported third-quarter 2026 revenue of US$624.6 million, up 15.6% from a year earlier and 5.7% sequentially. Those are sturdy numbers, especially for a business that investors have long tended to box in as...

Continue Reading
Hyster-Yale’s $135 Million Convert Carries Real Cost

Updated Category News Views 122

Forklift makers do not usually get to hide a 7.50% borrowing cost behind glossy financing jargon. Hyster-Yale has priced $135 million of convertible senior notes due in 2031, lifting the deal from the originally announced $125 million. There is also an option for initial purchasers to take another $20 million. For NYSE:HY shareholders, this is not a simple debt cleanup....

Continue Reading
Shenzhen Three-Way Summit Puts Stability to the Test

Updated Category News Views 153

Three nuclear powers sharing a room in Shenzhen is the sort of headline that makes every risk desk sit upright, even when the paperwork remains thin. CGTN reports that Chinese President Xi Jinping, Russian President Vladimir Putin and U.S. President Donald Trump met on November 19, 2026, in an unprecedented trilateral summit and issued a Declaration toward Peace. That is...

Continue Reading
EmTech AI 2027 Puts AI Ambitions Through Reality Test

Updated Category News Views 111

A three-day gathering cannot settle AI's biggest arguments, but MIT Technology Review has picked the right fight for EmTech AI 2027: make the industry face a Reality Test. The conference runs May 11–13, 2027, at MIT's campus and online, and that theme lands because the AI conversation has spent plenty of time admiring the engine while skipping the ugly maintenance bill....

Continue Reading
Liquidity Services Faces a Brutal Revenue Reality Check

Updated Category News Views 0

A 19.17% opening haircut is the market ringing the fire alarm, not politely clearing its throat. Liquidity Services reported fiscal fourth-quarter revenue of $106.4 million, roughly 10% below the prior-year quarter, and shareholders got hit hard on November 19, 2026. That reaction is ugly, but it is not mysterious. When a company built around moving surplus inventory...

Continue Reading
Nvidia Lawsuit Allegations Put Disclosure Risk in Focus

Updated Category News Views 67

A lawsuit notice can turn a roaring chip story sour in a hurry, and this one deserves a cold, careful read rather than the usual internet stampede. DJS Law Group says it has filed a securities class action against NVIDIA, alleging that the company made materially false and misleading statements during a stated class period running from October 9, 2025 through November 8,...

Continue Reading
L’Oréal’s Women of Worth Shows Why Brand Patience Matters

Updated Category News Views 61

Twenty-one years is a long time to keep a corporate promise from turning into wallpaper. L’Oréal Paris gathered its 2026 Women of Worth class at the Ebell in Los Angeles on November 18, recognizing 10 nonprofit leaders working on problems that do not yield to a glitzy evening or a tidy slogan. That distinction matters. Cancer survivorship, trafficking prevention,...

Continue Reading
Tongwei's 846 MW Romania Deal Tests Solar Supply Scale

Updated Category News Views 134

Eight hundred forty-six megawatts of panels do not quietly roll out the factory gate. Tongwei’s supply agreement with Rezolv Energy for Romania’s Dama Solar project is a hefty piece of utility-scale solar business, and the first truckload has already left Tongwei’s Nantong facility. That matters more than another polished signing-ceremony photo: equipment is moving,...

Continue Reading
AIM Academy Accreditation Signals a Broader Quality Push

Updated Category News Views 50

Early-childhood education does not hand out many clean, easily comparable scorecards, which is precisely why AIM Academy’s new Cognia recognition deserves a closer look. The Alabama provider has earned Cognia Initial Accreditation, while its Pike Road center received Accreditation with Merit after its Initial Accreditation Review. That is not a revenue event, not a...

Continue Reading
Satellite NTN's $3.22B Promise Needs Real Receipts

Updated Category News Views 64

Dead zones over oceans, deserts, and flight paths are finally becoming a serious commercial problem, not merely a neat engineering demo. That is the muscle behind the satellite non-terrestrial network, or NTN, pitch: connect aircraft, vessels, remote assets, and scattered sensors where terrestrial networks simply do not reach. MarketsandMarkets projects this market will...

Continue Reading

Top 5 Most Recently Viewed Articles

Stantec Gears Up for Q2 2025 Results and Insights Call

Updated Category News Views 119

Stantec Prepares for Q2 2025 Financial Results EDMONTON, Alberta — Stantec, recognized globally for its commitment to sustainable design and engineering, is gearing up to release its second quarter 2025 financial results shortly after market closure on a Wednesday in mid-August. The company’s steadfast dedication to enhancing communities through innovation and...

Continue Reading
Hyundai Motor's INITIUM: A Step Towards Hydrogen Mobility

Updated Category News Views 168

Hyundai Motor Explores a Hydrogen Future with INITIUM Concept Hyundai Motor Company recently held an inspiring event named 'Clearly Committed,' demonstrating its dedication to a future powered by hydrogen fuel technology. During this event, the company unveiled its latest hydrogen fuel cell electric vehicle (FCEV) concept, the INITIUM. The Meaning Behind INITIUM The term...

Continue Reading
Target Hospitality Enhances Community Capacity to Meet Demand

Updated Category News Views 130

Target Hospitality Expands Modular Accommodations Target Hospitality Corp. (NASDAQ: TH), a leading provider in the hospitality sector, recently announced a significant expansion of its modular accommodation community. This upgrade represents a 160% increase from their initial offering, aimed at meeting the surging demands of clients in the growing data center industry....

Continue Reading
Nutex Health's Legal Challenge: Misclaimed Bills & Investor Impact

Updated Category News Views 193

Nutex Health Faces Serious Legal Scrutiny Nutex Health Inc. (NASDAQ: NUTX), a company that operates micro-hospitals and healthcare facilities, finds itself in a challenging position as it deals with a class-action lawsuit. This litigation accuses the company of engaging in deceptive billing practices intended to inflate its financial performance. The lawsuit, filed in a...

Continue Reading
Exciting Developments in Uranium Exploration at Foremost Clean Energy

Updated Category News Views 194

Significant Findings at Hatchet Lake Project Foremost Clean Energy Ltd. (NASDAQ: FMST) has announced intriguing results from its latest drilling program at the Hatchet Lake Uranium Property, marking a significant milestone in its exploration efforts. These results stem from their rigorous winter drill program, which underscored the property’s potential for uranium...

Continue Reading